keyword
MENU ▼
Read by QxMD icon Read
search

Prophylactic Cranial Irradiation

keyword
https://www.readbyqxmd.com/read/28326834/thoracic-radiation-therapy-could-give-survival-benefit-to-elderly-patients-with-extensive-stage-small-cell-lung-cancer
#1
Changchun An, Wang Jing, Yan Zhang, Sujing Liu, Haiyong Wang, Kunli Zhu, Li Kong, Hongbo Guo, Hui Zhu
AIM: To evaluate the effect of thoracic radiation therapy (TRT) in elderly patients (aged ≥65 years) with extensive-stage small-cell lung cancer (ES-SCLC). PATIENTS & METHODS: This study reviewed the records of 118 elderly patients with ES-SCLC (all with distant metastasis) through January 2006-December 2013. The patients were divided into either a chemotherapy (ChT)/TRT-combination group or a ChT-alone group. RESULTS: The median survival time and 3-year overall survival rates in the ChT/TRT group were significantly higher than those in the ChT-alone group (17...
February 24, 2017: Future Oncology
https://www.readbyqxmd.com/read/28325618/thoracic-irradiation-in-3weeks-for-limited-stage-small-cell-lung-cancer-is-twice-a-day-fractionation-really-needed
#2
G A Turgeon, L Souhami, N Kopek, V Hirsh, L Ofiara, S L Faria
PURPOSE: Many Canadian institutions treat limited-disease small cell lung cancer with 40Gy in 15 fractions delivered once-a-day in 3weeks concomitantly with chemotherapy. This regimen is convenient and seems to be effective. Here, we report and compare with a literature review the outcomes of patients with limited-stage small cell lung cancer treated in our institution with this hypofractionated regimen. PATIENTS AND METHODS: From January 2004 to December 2012, patients with limited-stage small cell lung cancer treated curatively with platinum-based chemotherapy and concurrent thoracic radiotherapy at a dose of 40Gy in 16 fractions once-a-day were eligible for this review...
March 18, 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/28314330/prognostic-factors-and-treatment-of-early-stage-small-cell-lung-cancer
#3
Lukas Käsmann, Louisa Bolm, Stefan Janssen, Dirk Rades
BACKGROUND/AIM: Only 0.1-0.17% of all lung cancer patients are diagnosed with stage I or II small cell lung cancer (SCLC). Radiochemotherapy remains the standard treatment for limited stage disease. This study focused on prognostic factors in early stage SCLC treated with radiochemotherapy. PATIENTS AND METHODS: Seven factors in eight patients with early stage SCLC were analyzed concerning the impact on overall survival, namely gender, age, Karnofsky performance score, N-category, UICC-stage, concurrent chemotherapy and prophylactic cranial irradiation (PCI)...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28275490/erroneous-diagnosis-of-small-cell-lung-cancer-based-on-small-biopsies-with-far-reaching-consequences-case-report-of-a-typical-carcinoid-tumor
#4
Ioannis Kyritsis, Bettina Krebs, Sandra Kampe, Dirk Theegarten, Clemens Aigner, Stefan Welter
Although neuroendocrine tumors (NETs) of the lung are frequently discussed together, carcinoids are very different from high-grade small cell lung carcinoma (SCLC). SCLC is found in heavy-smoking, older patients, whereas smoking is not strongly associated with carcinoid tumors. We present the case of a 46-year-old never smoking woman who was misdiagnosed with SCLC. The patient was not responsive to radio-chemotherapy plus prophylactic cranial irradiation (PCI); she had a typical carcinoid (TC) tumor according to the final pathology report...
February 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28274393/low-dose-cranial-boost-in-high-risk-adult-acute-lymphoblastic-leukemia-patients-undergoing-bone-marrow-transplant
#5
William Su, Marcher Thompson, Ren-Dih Sheu, Amir Steinberg, Luis Isola, Richard Stock, Richard L Bakst
PURPOSE: Acute lymphoblastic leukemia (ALL) has a predilection for CNS involvement. Patients with high-risk ALL are often managed with transplant using a radiation-based conditioning regimen. Historically, a high-dose prophylactic cranial boost (CB) of ≥12 Gy was given to reduce risk of central nervous system (CNS) recurrence. However, the use of CB has fallen out of favor because of toxicity concerns. In high-risk adults undergoing transplant at our institution, we have used a low-dose 6 Gy CB to reduce toxicity while conditioning adults with fully developed brains...
March 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28202905/risk-factors-for-brain-metastases-after-prophylactic-cranial-irradiation-in-small-cell-lung-cancer
#6
Haiyan Zeng, Peng Xie, Xue Meng, Shuanghu Yuan, Xindong Sun, Wanlong Li, Bingjie Fan, Xiaolin Li, Jinming Yu
Despite administration of prophylactic cranial irradiation (PCI), some small cell lung cancer (SCLC) patients still suffer from brain metastases (BM) with unknown risk factors. We conducted this study to identify patients with higher BM risk after PCI and improve their outcome. The characteristics and survival of all the SCLC patients underwent PCI in our institute from 2003 to 2014 were analyzed. Kaplan-Meier method was applied to estimate BM free survival (BMFS) and overall survival (OS). Cox regression analyses were performed to explore risk factors for BM...
February 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28182655/regional-analysis-of-volumes-and-reproducibilities-of-automatic-and-manual-hippocampal-segmentations
#7
Fabian Bartel, Hugo Vrenken, Fetsje Bijma, Frederik Barkhof, Marcel van Herk, Jan C de Munck
PURPOSE: Precise and reproducible hippocampus outlining is important to quantify hippocampal atrophy caused by neurodegenerative diseases and to spare the hippocampus in whole brain radiation therapy when performing prophylactic cranial irradiation or treating brain metastases. This study aimed to quantify systematic differences between methods by comparing regional volume and outline reproducibility of manual, FSL-FIRST and FreeSurfer hippocampus segmentations. MATERIALS AND METHODS: This study used a dataset from ADNI (Alzheimer's Disease Neuroimaging Initiative), including 20 healthy controls, 40 patients with mild cognitive impairment (MCI), and 20 patients with Alzheimer's disease (AD)...
2017: PloS One
https://www.readbyqxmd.com/read/28169879/long-term-results-of-the-risk-adapted-treatment-for-childhood-b-cell-acute-lymphoblastic-leukemia-report-from-the-japan-association-of-childhood-leukemia-study-all-97-trial
#8
Keizo Horibe, Keiko Yumura-Yagi, Tooru Kudoh, Shinichiro Nishimura, Megumi Oda, Makoto Yoshida, Yoshihiro Komada, Junichi Hara, Akio Tawa, Ikuya Usami, Akihiko Tanizawa, Koji Kato, Ryoji Kobayashi, Keitaro Matsuo, Hiroki Hori
PURPOSE: This study was conducted as the first clinical trial by Japan Association of Childhood Leukemia Study to improve the outcome of B-cell acute lymphoblastic leukemia and explore a less toxic reinduction block. PATIENTS AND METHODS: From 1997 to 2002, 563 patients with B-cell acute lymphoblastic leukemia aged 1 to 15 years were enrolled. The patients were assigned into 4 risk groups (standard, intermediate, high, or extremely high risk) and treated with regimens intensified according to the risk...
March 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/28154994/neutrophil-to-lymphocyte-ratio-predicts-outcome-in-limited-disease-small-cell-lung-cancer
#9
Lukas Käsmann, Louisa Bolm, Steven E Schild, Stefan Janssen, Dirk Rades
INTRODUCTION: Patients with limited disease small-cell lung cancer (SCLC) receive radiochemotherapy followed by prophylactic cranial irradiation. The prognosis of these patients remains poor with a median survival of 16-24 months. Systemic inflammation was suggested as an important prognostic factor for outcomes. This study investigated the impact of systemic inflammation measured with neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) at first diagnosis in patients with limited disease SCLC for outcomes...
February 2, 2017: Lung
https://www.readbyqxmd.com/read/28127669/neuron-specific-enolase-and-response-to-initial-therapy-are-important-prognostic-factors-in-patients-with-small-cell-lung-cancer
#10
M Zhou, Z Wang, Y Yao, H Zhou, M Liu, J Sun
PURPOSE: The prognostic factors for the survival of small cell lung cancer (SCLC) patients are still widely debated. The aim of this study was to identify the clinical features and prognostic factors in SCLC patients. METHODS: A retrospective study was conducted on SCLC patients who were treated in our hospital between July 2010 and July 2015. Comparison of overall survival (OS) was performed using the Kaplan-Meier method. Prognostic factors for OS were identified by multivariate Cox regression models...
January 26, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/28123595/research-progress-in-the-treatment-of-small-cell-lung-cancer
#11
Yan-Fang Qiu, Zhi-Gang Liu, Wen-Juan Yang, Yu Zhao, Jiao Tang, Wei-Zhi Tang, Yi Jin, Fang Li, Rui Zhong, Hui Wang
Small cell lung cancer (SCLC) accounts for approximately 10-15% of all lung cancers. No significant improvement has been made for patients with SCLC in the past several decades. The main progresses were the thoracic radiation and prophylactic cranial irradiation (PCI) that improved the patient survival rate. For patients with limited disease and good performance status (PS), concurrent chemoradiotherapy (CCRT) followed by PCI should be considered. For extensive disease, the combination of etoposide and platinum-based chemotherapy remains the standard treatment and consolidative thoracic radiotherapy is beneficial for patients who have a significant respond to initial chemotherapy...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28115108/prophylactic-cranial-irradiation-or-no-prophylactic-cranial-irradiation-after-adjuvant-chemotherapy-in-resected-small-cell-lung-cancer
#12
EDITORIAL
Cecile Le Pechoux
No abstract text is available yet for this article.
February 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28109544/cost-effectiveness-of-prophylactic-cranial-irradiation-with-hippocampal-avoidance-in-limited-stage-small-cell-lung-cancer
#13
Xuanlu M Qu, Mark V Mishra, Glenn S Bauman, Ben Slotman, Minesh Mehta, Vinai Gondi, Alexander V Louie
BACKGROUND AND PURPOSE: Prophylactic cranial irradiation (PCI) in limited stage small cell lung cancer (LS-SCLC) prevents brain metastases and improves survival, with the potential for neurocognitive toxicity. RTOG0933 demonstrated that hippocampal avoidance (HA) during whole brain radiotherapy preserves neurocognition. This study's objective was to evaluate the cost-effectiveness of HA-PCI in LS-SCLC through decision analysis. MATERIALS AND METHODS: A Markov model was developed to simulate the clinical course of LS-SCLC who received HA-PCI or conventional PCI (C-PCI)...
January 18, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28073578/prophylactic-cranial-irradiation-after-definitive-chemoradiotherapy-for-limited-stage-small-cell-lung-cancer-do-all-patients-benefit
#14
Ahsan S Farooqi, Emma B Holliday, Pamela K Allen, Xiong Wei, James D Cox, Ritsuko Komaki
PURPOSE: Prophylactic cranial irradiation (PCI) can improve overall survival (OS) and suppress brain metastases (BM) in patients with limited-stage small cell lung cancer (LS-SCLC) after complete response to primary therapy. However, PCI can be toxic. We sought to identify characteristics of patients who may not benefit from PCI. METHODS: We identified 658 patients who received chemoradiotherapy at MD Anderson in 1986-2012; 364 received PCI and 294 did not. Median follow-up time was 21...
February 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28065620/treatment-response-and-prophylactic-cranial-irradiation-are-prognostic-factors-in-a-real-life-limited-disease-small-cell-lung-cancer-patient-cohort-comprehensively-staged-with-cranial-magnetic-resonance-imaging
#15
Chukwuka Eze, Olarn Roengvoraphoj, Maximilian Niyazi, Guido Hildebrandt, Rainer Fietkau, Claus Belka, Farkhad Manapov
INTRODUCTION: Prophylactic cranial irradiation (PCI) has proven to decrease the incidence of brain metastases (BMs), with a modest improvement in survival. PATIENTS AND METHODS: The impact of PCI was evaluated in 184 patients treated with chemoradiotherapy. PCI was applied to patients with disease with partial and complete response only when cranial magnetic resonance imaging before and after primary treatment revealed no BMs. Correlation between PCI and overall survival (OS), BM-free survival (BMFS), and time to progression (TTP) was analyzed to describe survival within subgroups...
November 21, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28027850/nine-year-experience-prophylactic-cranial-irradiation-in-extensive-disease-small-cell-lung%C3%A2-cancer
#16
Denise Bernhardt, Sebastian Adeberg, Farastuk Bozorgmehr, Nils Opfermann, Juliane Hoerner-Rieber, Michael C Repka, Jutta Kappes, Michael Thomas, Helge Bischoff, Felix Herth, Claus Peter Heußel, Jürgen Debus, Martin Steins, Stefan Rieken
BACKGROUND: In 2007, the European Organization for Research and Treatment of Cancer (EORTC) study (ClinicalTrials.gov identifier, NCT00016211) demonstrated a beneficial effect on overall survival (OS) with the use of prophylactic cranial irradiation (PCI) for extensive disease (ED) small-cell lung cancer (SCLC). Nevertheless, debate is ongoing regarding the role of PCI, because the patients in that trial did not undergo magnetic resonance imaging (MRI) of the brain before treatment. Also, a recent Japanese randomized trial showed a detrimental effect of PCI on OS in patients with negative pretreatment brain MRI findings...
December 2, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28011047/multi-institutional-experience-of-stereotactic-ablative-radiation-therapy-for-stage-i-small-cell-lung-cancer
#17
Vivek Verma, Charles B Simone, Pamela K Allen, Sameer R Gajjar, Chirag Shah, Weining Zhen, Matthew M Harkenrider, Christopher L Hallemeier, Salma K Jabbour, Chance L Matthiesen, Steve E Braunstein, Percy Lee, Thomas J Dilling, Bryan G Allen, Elizabeth M Nichols, Albert Attia, Jing Zeng, Tithi Biswas, Peter Paximadis, Fen Wang, Joshua M Walker, John M Stahl, Megan E Daly, Roy H Decker, Russell K Hales, Henning Willers, Gregory M M Videtic, Minesh P Mehta, Steven H Lin
PURPOSE: For inoperable stage I (T1-T2N0) small cell lung cancer (SCLC), national guidelines recommend chemotherapy with or without conventionally fractionated radiation therapy. The present multi-institutional cohort study investigated the role of stereotactic ablative radiation therapy (SABR) for this population. METHODS AND MATERIALS: The clinical and treatment characteristics, toxicities, outcomes, and patterns of failure were assessed in patients with histologically confirmed stage T1-T2N0M0 SCLC...
February 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27981260/once-daily-high-dose-radiation-%C3%A2-60-gy-treatment-in-limited-stage-small-cell-lung-cancer
#18
Amir Zahra, Tangel Chang, Taher Abu Hejleh, Muhammad Furqan, Gerald H Clamon, Sudershan K Bhatia, John M Watkins, Sarah L Mott, Logan L Ahmann, Kellie L Bodeker, Douglas R Spitz, John M Buatti, Bryan G Allen
BACKGROUND: To investigate outcomes and prognostic factors in patients treated with once daily high-dose (≥60 Gy) radiation therapy (HDRT) and concurrent platinum-based chemotherapy in limited stage small cell lung cancer (LS-SCLC). While we await current phase III trials to determine optimal radiation dose fractionation schemes in LS-SCLC, we report our experience in LS-SCLC with once daily HDRT. We hypothesized that HDRT would achieve similar efficacy and tolerability as twice daily therapy...
November 2016: J Oncol Transl Res
https://www.readbyqxmd.com/read/27978874/-concurrent-chemoradiotherapy-with-original-chemotherapy-regimens-may-not-be-suitable-for-patients-who-failed-to-respond-to-induction-chemotherapy%C3%A2-in-limited-stage-small-cell-lung-cancer
#19
Daquan Wang, Liming Xu, Lujun Zhao, Wencheng Zhang, Qingsong Pang, Ningbo Liu, Xi Chen, Xiuli Chen, Zhiyong Yuan, Ping Wang
BACKGROUND: The group of small cell lung cancer (SCLC) are usually highly sensitive to chemotherapy, and less than 15% of them are resistant to drugs. We respectively evaluate the correlation of the sequence and timing of radiotherapy with progression-free survival (PFS) and overall survival (OS) in patients with limited-stage SCLC (LS-SCLC), and to figure out whether concurrent chemoradiotherapy is superior to sequent chemoradiotherapy. METHODS: Sixty-seven patients diagnosed with LS-SCLC from January 2009 to June 2014 failed to respond to induction chemotherapy...
December 20, 2016: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/27969462/mini01-15-prophylactic-cranial-irradiation-pci-for%C3%A2-limited-small-cell-lung-cancer-lsclc-an-iaslc-physician-survey-topic-radiation-oncology
#20
Laurie E Gaspar, Françoise Mornex, Feng-Ming Spring Kong, Fred Hirsch
No abstract text is available yet for this article.
November 2016: Journal of Thoracic Oncology
keyword
keyword
13187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"